title: Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma.
abstract: Esophageal squamous cell carcinoma (ESCC) is one of the most common tumors worldwide, with a high malignant degree and poor prognosis. The present study aims to investigate the relationship between pyruvate kinase M2 (PKM2) expression and the prognosis of patients with ESCC. The expression of PKM2 in 86 cases of esophageal carcinoma tissues was tested using immunohistochemistry. The relationship between PKM2 expression and clinical pathological parameters, and their effects on the prognosis of patients with ESCC were analyzed. The expression levels of PKM2 in both cytoplasm and nucleus of ESCC tissues were significantly higher than those in paracancerous tissues (P=6.73×10(-9) and 4.32×10(-6), respectively). The Kaplan-Meier analysis showed that nuclear PKM2 expression was closely related to the survival of patients with ESCC (P=0.005). Patients with high PKM2 expression in the nucleus had significantly shorter survival times than those with low PKM2 expression in the nucleus (hazard ratio for death, 2.358; 95% confidence interval, 1.156-4.812; P=0.018). No other significant difference was found between PMK2 expression and clinico-pathological features of ESCC patients (all P>0.05). In conclusion, high PKM2 expression in the nucleus is essential in the pathogenic process of ESCC and may be used to predict the prognosis of patients with ESCC.
authors.affiliation: Department of Thoracic Surgery, Taizhou Central Hospital, Taizhou, Zhejiang, China.
authors.forename: Xuelin
authors.initials: X
authors.lastname: Zhang
authors.forename: Chengzhi
authors.initials: C
authors.lastname: He
authors.forename: Chunya
authors.initials: C
authors.lastname: He
authors.forename: Baofu
authors.initials: B
authors.lastname: Chen
authors.forename: Yanxia
authors.initials: Y
authors.lastname: Liu
authors.forename: Min
authors.initials: M
authors.lastname: Kong
authors.forename: Chunguo
authors.initials: C
authors.lastname: Wang
authors.forename: Lizhong
authors.initials: L
authors.lastname: Lin
authors.forename: Yan
authors.initials: Y
authors.lastname: Dong
authors.forename: Haihui
authors.initials: H
authors.lastname: Sheng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D002352:Carrier Proteins / Q000032:analysis*; D002467:Cell Nucleus / Q000201:enzymology*; D016009:Chi-Square Distribution; D004938:Esophageal Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008565:Membrane Proteins / Q000032:analysis*; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D013963:Thyroid Hormones / Q000032:analysis*; D013997:Time Factors; D046888:Tissue Array Analysis; D015854:Up-Regulation; D000097810:Thyroid Hormone-Binding Proteins
chemical_list: D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D008565:Membrane Proteins; D013963:Thyroid Hormones; D000097810:Thyroid Hormone-Binding Proteins
keywords: Esophageal squamous cell carcinoma; Glycolysis; Pyruvate kinase M2; Survival